Atractylenolide I

TargetMol
Product Code: TAR-T5S0167
Supplier: TargetMol
CodeSizePrice
TAR-T5S0167-1mg1mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5S0167-5mg5mg£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5S0167-1mL1 mL * 10 mM (in DMSO)£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5S0167-10mg10mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5S0167-25mg25mg£274.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5S0167-50mg50mg£429.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5S0167-100mg100mg£571.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
1. Atractylenolide-I has an anti-inflammatory effect by inhibiting TNF-α and IL-6 production; ameliorates sepsis syndrome, liver and kidney functions by reduction of pro-inflammatory cytokines and LPS. 2. Atractylenolide-I significantly sensitizes the response of MyD88(+) EOC cells to paclitaxel by blocking MD-2-mediated TLR4/MyD88 signaling.
CAS:
73069-13-3
Formula:
C15H18O2
Molecular Weight:
230.307
Pathway:
Chromatin/Epigenetic; Angiogenesis; Immunology/Inflammation; Stem Cells; Apoptosis; JAK/STAT signaling
Purity:
0.9755
SMILES:
CC1=C2C[C@H]3C(=C)CCC[C@]3(C)C=C2OC1=O
Target:
IL Receptor; TNF; TLR; JAK; STAT

References

Wang F, Li Z, Chen L, et al. Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1?/NF-?B feedback pathway to inhibit liver fibrosis. Acta Pharmaceutica Sinica B. 2022 Ji G , Chen R , Zheng J . Atractylenolide I inhibits lipopolysaccharide-induced inflammatory responses via mitogen-activated protein kinase pathways in RAW264.7 cells[J]. Immunopharmacology and Immunotoxicology, 2014, 36(6):420-425. Yu Z, Niu P, Su Z, et al.Role of Atractylenolide I in Cerebral Ischemia Reperfusion Injury.Revista Brasileira de Farmacognosia.2023: 1-10.